Single peptide Vial strength 10 mg
PT-14110 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
PT-141, explained simply
Bremelanotide acts through the melanocortin pathway. Its molecule, approved indication, and formulation need to be considered separately.
Research area
Sexual health
How it works
PT-141, or bremelanotide, acts on central melanocortin receptor pathways involved in sexual response.
Why it matters
It illustrates the distinction between an active molecule and the particular formulation that was studied and authorized.
What has been observed
Bremelanotide clinical trials address sexual desire in a defined indication.
Effects and points to consider
Evidence for an approved product does not automatically apply to a generic reconstituted vial.
01 / Vial strength 10 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 10 mg PT-141 |
|---|---|
| Final volume | 3 mL |
| Concentration | 3.33 mg/mL |
| One U-100 unit | 33.33 mcg in 0.01 mL |
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
Nasal Actuation Calculation Table (Placeholders)
| Concentration (mcg/mL) | Pump Output (mL/actuation) | Amount per Actuation (mcg) | Actuations per mL | Total Actuations in Reconstituted Volume |
|---|---|---|---|---|
| [A] | [B] | [A] × [B] | 1 / [B] | [Recon. vol. mL] × (1 / [B]) |
| [C] | [D] | [C] × [D] | 1 / [D] | [Recon. vol. mL] × (1 / [D]) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.